Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (Q3)Sep 30, 2023 | (Q2)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 112.82%72.57M | 2,560.46%82.9M | 4,351.91%106M | 99.11M | 59.51M | 7.86%34.1M | 3.12M | 2.38M | -76.96%31.61M | 87.64M |
| Cost of revenue | 114.48%69.6M | 2,536.83%79.11M | 5,962.39%103M | 94.85M | 57.7M | 29.34%32.45M | 3M | 1.7M | -62.13%25.09M | 68.94M |
| Gross profit | 80.17%2.97M | 3,171.55%3.8M | 339.88%3M | 4.25M | 1.81M | -74.73%1.65M | 116K | 682K | -90.81%6.53M | 18.7M |
| Operating expense | 4,654.52%15.12M | -32.95%2.44M | -501.45%-1.66M | 5.25M | -1.51M | -100.72%-332K | 3.64M | 413K | -31.09%45.97M | 13.85M |
| Selling and administrative expenses | 129.11%2.39M | 365.86%2.51M | 174.69%2.64M | --5.25M | --2.71M | -97.77%1.04M | --539K | --960K | 2,192.62%46.61M | --13.83M |
| -General and administrative expense | 129.11%2.39M | 365.86%2.51M | 174.69%2.64M | --5.25M | --2.71M | -97.77%1.04M | --539K | --960K | 2,192.62%46.61M | --13.83M |
| Other operating expenses | --12.78M | ---- | ---- | --5.5M | ---- | ---- | --3.31M | --3.33M | ---- | --330K |
| Total other operating income | -96.94%42K | -65.89%73K | 10.70%4.3M | --8.54M | --4.22M | 114.87%1.37M | --214K | --3.88M | --639K | --308K |
| Operating profit | -713.33%-12.15M | 138.55%1.36M | 1,631.60%4.66M | -995K | 3.32M | 105.02%1.98M | -3.52M | 269K | -1,024.20%-39.45M | 4.85M |
| Net non-operating interest income (expenses) | -200.00%-3K | 75.00%-2K | 80.00%-2K | -19K | 0 | 93.75%-1K | -8K | -10K | -1,500.00%-16K | -19K |
| Non-operating interest expense | 200.00%3K | -75.00%2K | -80.00%2K | --19K | --0 | -93.75%1K | --8K | --10K | 1,500.00%16K | --19K |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | ||||||||||
| Other non-operating income (expenses) | 3.11M | |||||||||
| Income before tax | -713.79%-12.15M | 138.41%1.36M | 1,697.68%4.66M | 2.1M | 3.32M | 105.02%1.98M | -3.53M | 259K | -1,024.79%-39.46M | 4.83M |
| Income tax | -148.57%-17K | -73.85%17K | -62.50%9K | 138K | 13K | 100.61%35K | 65K | 24K | -231.40%-5.71M | 739K |
| Net income | -723.96%-12.14M | 137.24%1.34M | 1,877.45%4.65M | 1.96M | 3.3M | 105.76%1.95M | -3.59M | 235K | -663.46%-33.75M | 4.09M |
| Net income continuous operations | -723.96%-12.14M | 137.24%1.34M | 1,877.45%4.65M | --1.96M | --3.3M | 105.76%1.95M | ---3.59M | --235K | -663.46%-33.75M | --4.09M |
| Noncontrolling interests | 0 | 0 | 0 | 75K | 0 | 0 | -44K | 119K | 86.56%-1.46M | 974K |
| Net income attributable to the company | -723.96%-12.14M | 137.70%1.34M | 3,906.03%4.65M | 1.88M | 3.3M | 106.02%1.95M | -3.55M | 116K | -291.36%-32.29M | 3.12M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -723.96%-12.14M | 137.70%1.34M | 3,906.03%4.65M | 1.88M | 3.3M | 106.02%1.95M | -3.55M | 116K | -291.36%-32.29M | 3.12M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -706.25%-0.0097 | 139.29%0.0011 | 3,600.00%0.0037 | 0.0015 | 0.0026 | 106.04%0.0016 | -0.0028 | 0.0001 | -240.21%-0.0265 | 0.0026 |
| Diluted earnings per share | -706.25%-0.0097 | 139.29%0.0011 | 3,600.00%0.0037 | 0.0015 | 0.0026 | 106.04%0.0016 | -0.0028 | 0.0001 | -245.60%-0.0265 | 0.0025 |
| Dividend per share | ||||||||||
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.